Back to Search
Start Over
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
- Source :
- Lupus Science and Medicine, Vol 7, Iss 1 (2020), Lupus Science & Medicine
- Publication Year :
- 2020
- Publisher :
- BMJ, 2020.
-
Abstract
- ObjectiveDisease severity in SLE is an important concept related to disease activity, treatment burden and prognosis. We set out to evaluate if high disease activity status (HDAS), based on ever attainment of a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) disease activity score of ≥10, is an indicator for disease severity in SLE.MethodsUsing prospectively collected data, we assessed the association of HDAS with sociodemographic and disease characteristics and adverse clinical outcomes using logistic regression or generalised estimating equations.ResultsOf 286 patients with SLE, who were observed for a median (range) of 5.1 years (1–10.8 years), 43.7% experienced HDAS at least once during the observational period. Autoantibody positivity, particularly anti-dsDNA and anti-Sm positivity, were associated with increased likelihood of HDAS. Age ≥45 years at diagnosis was associated with reduced likelihood of HDAS (p=0.002). Patients with HDAS had higher Physician Global Assessment score (>1: OR 8.1, p0.001), higher corticosteroid exposure (corticosteroid dose in highest quartile: OR 7.7, 95% CI 3.9 to 15.3; pConclusionsHDAS is associated with more severe disease, as measured by higher disease activity across time, corticosteroid exposure and damage accrual. The occurrence of HDAS may be a useful prognostic marker in the management of SLE.
- Subjects :
- Male
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
medicine.drug_class
Immunology
Severe disease
Logistic regression
Severity of Illness Index
Disease activity
Cost of Illness
systemic lupus erythematosus
Adrenal Cortex Hormones
Internal medicine
medicine
Humans
Lupus Erythematosus, Systemic
autoimmune diseases
Aged
Autoantibodies
Retrospective Studies
business.industry
Australia
Autoantibody
General Medicine
Middle Aged
Prognosis
Epidemiology and Outcomes
Rheumatology
Clinical trial
Logistic Models
Quartile
Case-Control Studies
Disease Progression
Corticosteroid
Female
lcsh:RC581-607
business
disease activity
Subjects
Details
- ISSN :
- 20538790
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Lupus Science & Medicine
- Accession number :
- edsair.doi.dedup.....949957c9eb34cde0a7ed99dc7f3af62e
- Full Text :
- https://doi.org/10.1136/lupus-2019-000372